High prevalence of benign prostatic hypertrophy in the community

Garraway, W. M.; Lee, R.J.; Collins, Gerald N.

doi:10.1016/0140-6736(91)90543-x

Cited by 718 publications

(400 citation statements)

References 9 publications

Supporting

Mentioning

373

Contrasting

Unclassified

Order By: Relevance

“…The diminishing importance of baseline symptoms for certain endpoints is potentially related to the improvement of the symptoms after radiotherapy treatment shown here and similarly reported by others [26,[32][33][34]. Related to this, increasing age is associated with lower risk for dysuria which might be associated to the shrinkage of benign hypertrophic prostate after radiotherapy treatment which is more prevalent in older patients [35].…”

Section: Discussionsupporting

confidence: 80%

Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy: An analysis of data from the RADAR prostate radiotherapy trial

Yahya

Ebert

Bulsara

et al. 2015

Radiotherapy and Oncology

View full text Add to dashboard Cite

Urinary symptoms (frequency, incontinence, dysuria and haematuria) were prospectively assessed using LENT-SOMA to a median of 72 months. The endpoints assessed were prevalence (grade≥1) at the end of radiotherapy (representing acute symptoms), at 18-, 36-and 54-month follow-ups (representing late symptoms) and peak late incidence including only grade≥2. Impact of factors were assessed using multivariate logistic regression models with correction for over-optimism. Results: Baseline symptoms, non-insulin dependent diabetes mellitus, age and PC1 (correlated to the mean dose) impact symptoms at >1 timepoints. Associations at a single timepoint were found for cerebrovascular condition, ECOG status and non-steroidal anti-inflammatory drug intake. Peak incidence analysis shows the impact of baseline, bowel and cerebrovascular condition and smoking status. Conclusions:The prevalence and incidence analysis provide a complementary view for urinary symptom prediction. Sustained impacts across time points were found for several factors while some associations were not repeated at different time points suggesting poorer or transient impact.4

show abstract

Section: Discussionsupporting

confidence: 80%

Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy: An analysis of data from the RADAR prostate radiotherapy trial

Yahya

Ebert

Bulsara

et al. 2015

Radiotherapy and Oncology

View full text Add to dashboard Cite

show abstract

“…The prevalence of BPH in Western countries is estimated at 40%-70% and in the Korean population at ∼40% [1,2]. Recent study strongly suggests that BPH is an autoimmune inflammatory disease [3].…”

Section: Introductionmentioning

confidence: 99%

Nitric oxide synthase 2 gene polymorphisms are associated with prostatic volume in Korean men with benign prostatic hyperplasia

Yoo¹,

Kim²,

Chung³

et al. 2010

Asian J Androl

View full text Add to dashboard Cite

The precise aetiology of benign prostatic hyperplasia (BPH) remains unclear; however, it is known that immunological inflammatory processes have a role in the pathogenesis of BPH initiation and progression. Nitric oxide synthase 2 (NOS2) inducible expression is closely correlated with prostatic disease, including prostate cancer and BPH. The aim of this study was to investigate the relationship between NOS2 polymorphisms and BPH. With a cohort of 205 controls and 229 BPH subjects, we genotyped three single nucleotide polymorphisms (SNPs) in the NOS2 gene, including rs2779248 (promoter, −278 T/C), rs10459953 (5′-untranslated region) and rs2297518 (exon 16, missense, Ser608Leu), using direct sequencing and restriction fragment length polymorphism. The genotypic and allelic frequencies between control and BPH subjects were compared, and the associations among the BPH subjects were analyzed. SNPStats, SNPAnalyzer and HelixTree programmes were used to analyze SNPs. There was no association on SNPs between control and BPH subjects. When BPH subjects were analyzed, there was no association on SNPs between the low and high prostate-specific antigen groups. However, one SNP (rs10459953, odds ratio [OR] = 0.44, 95% confidence interval [CI] = 0.29-0.65, P < 0.0001, in codominant model; OR = 0.23, 95% CI = 0.12-0.46, P < 0.0001, in dominant model; and OR = 0.46, 95% CI = 0.24-0.86, P = 0.015, in recessive model) was associated with prostatic volume in BPH. We detected a strong association in genotype frequencies of NOS2 SNP (rs10459953) between subjects with small and large prostatic volume in BPH. The result suggests that NOS2 may be associated with prostatic volume in BPH.

show abstract

“…For example, a population survey in Minnesota showed that 13% of men aged 40±49 y and 28% of men over 70 y had moderate-to-severe obstructive symptoms; 1 while in a Scottish population survey higher prevalence rates of 14 and 43% for men in the ®fth and seventh decades, respectively, were found using a de®ni-tion of BPH based on the size of the prostate. 2 In addition, pooled results of several autopsy studies indicated that the numbers of men with BPH (meeting histological criteria) rises with age, with 88% of men aged over 80 y having histological disease. 3 Hypertension is also a common age-related disorder.…”

Section: Introductionmentioning

confidence: 99%

Doxazosin in the treatment of benign prostatic hyperplasia. A review of the safety profile in older patients

Kirby

Jardin

1997

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

The objective of this paper is to review the safety of doxazosin in older patients ( ! 65 y) with benign prostatic hyperplasia (BPH) as reported in seven international clinical trials. Data from seven double-blind, placebo-controlled, phase III trials, in both normotensive and hypertensive patients with BPH were collated and analysed. Data on doxazosin were available for 341 men 65 y and over. Even though older patients can be at particular risk of adverse drug reactions, there was no apparent evidence of poor tolerability with doxazosin in older patients with BPH. The percentages of younger normotensive BPH patients (`65 y) experiencing at least one adverse event were 47 and 44% for doxazosin and placebo groups, respectively; for older normotensive BPH patients ( ! 65 y) the corresponding values were 42 and 38%. For the younger hypertensive BPH patients the incidence rates for adverse events were 55% (doxazosin) and 42% (placebo) and for older hypertensive BPH patients 43 and 30%, respectively. The most commonly reported adverse events for all groups were dizziness, headache and fatigue and few serious adverse effects were reported throughout these trials. It can be concluded that doxazosin is well tolerated in young and old, normotensive and hypertensive patients with BPH.

show abstract

High prevalence of benign prostatic hypertrophy in the community

Cited by 718 publications

References 9 publications

Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy: An analysis of data from the RADAR prostate radiotherapy trial

Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy: An analysis of data from the RADAR prostate radiotherapy trial

Nitric oxide synthase 2 gene polymorphisms are associated with prostatic volume in Korean men with benign prostatic hyperplasia

Doxazosin in the treatment of benign prostatic hyperplasia. A review of the safety profile in older patients

Contact Info

Product

Resources

About